Search This Blog

Thursday, September 22, 2022

Vir Biotechnology Starts Phase 2 Trial Evaluating VIR-2218 and VIR-3434 for Chronic Hep D

  Impacting more than 12 million people globally, HDV is the most aggressive form of viral hepatitis 

– Novel combination strategy designed to
reduce HDV viremia and block viral entry –

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.